Central laboratory services for phase I/IIa clinical trials of a bispecific antibody combination for BiconY Therapeutics GmbH, including specimen management and cytokine analysis.

The Federal Agency for Disruptive Innovation (SPRIND) subsidiary, BiconY Therapeutics GmbH, is conducting phase I/IIa clinical trials for a bispecific antibody combination to treat solid tumours. The project requires a central laboratory service provider to manage the logistics, processing, and analysis of biological specimens. Key tasks include cytokine multiplex analysis and PBMC isolation. The contract duration is 18 months with potential for extension. Bidders must demonstrate GCLP compliance and relevant experience in clinical study specimen management.

BiconY Therapeutics GmbH seeks a service provider for central laboratory services for phase I/IIa clinical trials. Services include collection logistics, processing, analysis of cytokines in serum, isolation of PBMC, and long-term storage of biological specimens.